Adicet Bio Inc

ACETNASDAQ · USD
2.78USD0.00 (-5.12%)
512

Adicet Bio Inc (ACET) Covered Calls

Read more

Running ACET covered calls helps you generate income from Adicet Bio Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ACET covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ACET stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ACET covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ACET covered call is worth writing.

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors.

No illustrative rows to display.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank5.56% Low
  • Market cap (M$)26
  • 52 weeks high-75.07%
  • 52 weeks low-2.11%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$29.00
    943.17% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-8.57
  • EPS growth next 5 years43.96%

As of Nov 13, 2026